XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.37

-1.3%

1:35 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (4940)	11/29/1997 6:32:00 PM
From: Robert K.	Read Replies (1) of 17367

First, dont let what that md said shake your confidence. Do make a mental note of it and weight it appropriately in your decisions. Liver 72 patient started about june 95. Consist of 12 patient low dose and "up to" 60 patient high dose phase. In Europe. That may be significant in itself. Significance. Partial hepatecomy(sp). Not many performed in usa, More so in europe. Market, not big. Investor interest, not much. Now for the good part. Liver is "I believe" responsible for clearance of endotoxin. Damaged or not functioning liver cant clear endotoxin. Endotoxin is implicated mediator of sepsis/shocks/ards etc. Additionally, liver surgery weakens gut-mucosal barrier, which they think may cause bacteria leak into bloodstream then sepsis/shock/ards etc. Now they can stop the trial at any point now, I believe at xomas option. Double blinded so results not really known. Ok so far. Continue to next note

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next